Cargando…
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
The term, preclinical dementia, was introduced in 2011 when new guidelines for the diagnosis of Alzheimer’s dementia (AD) were published. In the intervening 11 years, many studies have appeared in the literature focusing on this early stage. A search conducted in English on Google Scholar on 06.23.2...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729660/ https://www.ncbi.nlm.nih.gov/pubmed/36506684 http://dx.doi.org/10.1007/s10433-022-00735-w |
_version_ | 1784845517585383424 |
---|---|
author | Mark, Ruth E. Brehmer, Yvonne |
author_facet | Mark, Ruth E. Brehmer, Yvonne |
author_sort | Mark, Ruth E. |
collection | PubMed |
description | The term, preclinical dementia, was introduced in 2011 when new guidelines for the diagnosis of Alzheimer’s dementia (AD) were published. In the intervening 11 years, many studies have appeared in the literature focusing on this early stage. A search conducted in English on Google Scholar on 06.23.2022 using the term “preclinical (Alzheimer’s) dementia” produced 121, 000 results. However, the label is arguably more relevant for research purposes, and it is possible that the knowledge gained may lead to a cure for AD. The term has not been widely adopted by clinical practitioners. Furthermore, it is still not possible to predict who, after a diagnosis of preclinical dementia, will go on to develop AD, and if so, what the risk factors (modifiable and non-modifiable) might be. This Review/Theoretical article will focus on preclinical Alzheimer’s dementia (hereafter called preclinical AD). We outline how preclinical AD is currently defined, explain how it is diagnosed and explore why this is problematic at a number of different levels. We also ask the question: Is the concept ‘preclinical AD’ useful in clinical practice or is it just another dead end in the Holy Grail to find a treatment for AD? Specific recommendations for research and clinical practice are provided. |
format | Online Article Text |
id | pubmed-9729660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-97296602022-12-09 Preclinical Alzheimer’s dementia: a useful concept or another dead end? Mark, Ruth E. Brehmer, Yvonne Eur J Ageing Review The term, preclinical dementia, was introduced in 2011 when new guidelines for the diagnosis of Alzheimer’s dementia (AD) were published. In the intervening 11 years, many studies have appeared in the literature focusing on this early stage. A search conducted in English on Google Scholar on 06.23.2022 using the term “preclinical (Alzheimer’s) dementia” produced 121, 000 results. However, the label is arguably more relevant for research purposes, and it is possible that the knowledge gained may lead to a cure for AD. The term has not been widely adopted by clinical practitioners. Furthermore, it is still not possible to predict who, after a diagnosis of preclinical dementia, will go on to develop AD, and if so, what the risk factors (modifiable and non-modifiable) might be. This Review/Theoretical article will focus on preclinical Alzheimer’s dementia (hereafter called preclinical AD). We outline how preclinical AD is currently defined, explain how it is diagnosed and explore why this is problematic at a number of different levels. We also ask the question: Is the concept ‘preclinical AD’ useful in clinical practice or is it just another dead end in the Holy Grail to find a treatment for AD? Specific recommendations for research and clinical practice are provided. Springer Netherlands 2022-10-19 /pmc/articles/PMC9729660/ /pubmed/36506684 http://dx.doi.org/10.1007/s10433-022-00735-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Mark, Ruth E. Brehmer, Yvonne Preclinical Alzheimer’s dementia: a useful concept or another dead end? |
title | Preclinical Alzheimer’s dementia: a useful concept or another dead end? |
title_full | Preclinical Alzheimer’s dementia: a useful concept or another dead end? |
title_fullStr | Preclinical Alzheimer’s dementia: a useful concept or another dead end? |
title_full_unstemmed | Preclinical Alzheimer’s dementia: a useful concept or another dead end? |
title_short | Preclinical Alzheimer’s dementia: a useful concept or another dead end? |
title_sort | preclinical alzheimer’s dementia: a useful concept or another dead end? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729660/ https://www.ncbi.nlm.nih.gov/pubmed/36506684 http://dx.doi.org/10.1007/s10433-022-00735-w |
work_keys_str_mv | AT markruthe preclinicalalzheimersdementiaausefulconceptoranotherdeadend AT brehmeryvonne preclinicalalzheimersdementiaausefulconceptoranotherdeadend |